Neomycin/Polymyxin B/Dexametha
Brand names: Neomycin-Polymyxin-Dexameth
At a glance
- Medicare prescriptions, 2024
- 918,729
- Medicare drug cost
- $10.7M
- Average cost per prescription
- $11.61
- Clinicians who prescribed it
- 20,607
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.
From the FDA-approved prescribing information (label dated October 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Ophthalmology 57.8%
- Optometrists 32.1%
- Retina Specialist 2.3%
- Family Medicine 1.8%
- Internal Medicine 1.6%
- Nurse Practitioners 1.4%
- Physician Assistants 1.0%
- General Practice 0.7%
- Plastic Surgery 0.3%
- ENT (Otolaryngology) 0.3%
- Podiatrists 0.2%
- Facial Plastic Surgery 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 40% from 2019 to 2024.
Biggest change by state since 2019
- Colorado +72%
- Nevada +71%
- Maryland +65%
- Kentucky +56%
- Michigan +55%
- California (smallest change) +16%
- Hawaii (smallest change) +22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.